Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis

Renuka Mopuru; Shruti Chaturvedi; Bryn M. Burkholder

doi:10.1080/09273948.2020.1797117

Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis

Renuka Mopuru, Shruti Chaturvedi, Bryn M. Burkholder

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

Purpose: To report a case of relapsing thrombotic thrombocytopenic purpura (TTP) in a patient treated with infliximab for chronic uveitis. Case report: A 57-year-old African American woman with chronic anterior and intermediate uveitis, treated with infliximab for more than 1 year, presented with fatigue, dark colored urine, and ecchymosis on her extremities. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) and recovered after treatment. After a remission period of 8 months, she was treated again with infliximab for recurrent intraocular inflammation. She developed a relapse of TTP 4 weeks after reintroducing infliximab. Conclusion: Relapsing thrombotic thrombocytopenic purpura can be a rare complication associated with infliximab. To our knowledge, it has not been reported in the literature to date.

Original language	English (US)
Pages (from-to)	241-243
Number of pages	3
Journal	Ocular Immunology and Inflammation
Volume	30
Issue number	1
DOIs	https://doi.org/10.1080/09273948.2020.1797117
State	Published - 2022

Keywords

ADAMTS13
Thrombotic thrombocytopenic purpura
drug-induced thrombotic microangiopathy
infliximab
uveitis

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.1080/09273948.2020.1797117

Cite this

@article{8bddc6c6fbed42c881962558800720be,

title = "Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis",

abstract = "Purpose: To report a case of relapsing thrombotic thrombocytopenic purpura (TTP) in a patient treated with infliximab for chronic uveitis. Case report: A 57-year-old African American woman with chronic anterior and intermediate uveitis, treated with infliximab for more than 1 year, presented with fatigue, dark colored urine, and ecchymosis on her extremities. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) and recovered after treatment. After a remission period of 8 months, she was treated again with infliximab for recurrent intraocular inflammation. She developed a relapse of TTP 4 weeks after reintroducing infliximab. Conclusion: Relapsing thrombotic thrombocytopenic purpura can be a rare complication associated with infliximab. To our knowledge, it has not been reported in the literature to date.",

keywords = "ADAMTS13, Thrombotic thrombocytopenic purpura, drug-induced thrombotic microangiopathy, infliximab, uveitis",

author = "Renuka Mopuru and Shruti Chaturvedi and Burkholder, {Bryn M.}",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/09273948.2020.1797117",

language = "English (US)",

volume = "30",

pages = "241--243",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis

AU - Mopuru, Renuka

AU - Chaturvedi, Shruti

AU - Burkholder, Bryn M.

PY - 2022

Y1 - 2022

N2 - Purpose: To report a case of relapsing thrombotic thrombocytopenic purpura (TTP) in a patient treated with infliximab for chronic uveitis. Case report: A 57-year-old African American woman with chronic anterior and intermediate uveitis, treated with infliximab for more than 1 year, presented with fatigue, dark colored urine, and ecchymosis on her extremities. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) and recovered after treatment. After a remission period of 8 months, she was treated again with infliximab for recurrent intraocular inflammation. She developed a relapse of TTP 4 weeks after reintroducing infliximab. Conclusion: Relapsing thrombotic thrombocytopenic purpura can be a rare complication associated with infliximab. To our knowledge, it has not been reported in the literature to date.

AB - Purpose: To report a case of relapsing thrombotic thrombocytopenic purpura (TTP) in a patient treated with infliximab for chronic uveitis. Case report: A 57-year-old African American woman with chronic anterior and intermediate uveitis, treated with infliximab for more than 1 year, presented with fatigue, dark colored urine, and ecchymosis on her extremities. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) and recovered after treatment. After a remission period of 8 months, she was treated again with infliximab for recurrent intraocular inflammation. She developed a relapse of TTP 4 weeks after reintroducing infliximab. Conclusion: Relapsing thrombotic thrombocytopenic purpura can be a rare complication associated with infliximab. To our knowledge, it has not been reported in the literature to date.

KW - ADAMTS13

KW - Thrombotic thrombocytopenic purpura

KW - drug-induced thrombotic microangiopathy

KW - infliximab

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85091160075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091160075&partnerID=8YFLogxK

U2 - 10.1080/09273948.2020.1797117

DO - 10.1080/09273948.2020.1797117

M3 - Letter

C2 - 32945712

AN - SCOPUS:85091160075

SN - 0927-3948

VL - 30

SP - 241

EP - 243

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 1

ER -

Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this